Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation
Andrea Gramegna, Martina Contarini, Francesco Bindo, Stefano Aliberti, Francesco Blasi
Topics & Concepts
IvacaftorCystic fibrosisMedicineCystic fibrosis transmembrane conductance regulatorPopulationMutationDiseaseLimitingBioinformaticsIntensive care medicineInternal medicineBiologyGeneticsGeneEnvironmental healthEngineeringMechanical engineeringCystic Fibrosis Research AdvancesNematode management and characterization studies